Why Pfizer Remains A Strong Buy In 2026 (NYSE:PFE)

After Pfizer's Q4 report ( PFE ), which, as you know, was published on February 3, its stock was up 7%, outperforming the S&P 500 ( SPY ) [-5.7% return]. (These results came in after my last update on Pfizer, which was inWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and p ...